Immune restoration disease after antiretroviral therapy

AIDS

Volumn 18, Issue 12, 2004, Pages 1615-1627

  French, Martyn A ^a,b   Price, Patricia ^a   Stone, Shelley F ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b ROYAL PERTH HOSPITAL   (Australia)

Author keywords

Antiretroviral therapy; HIV; Immune reconstitution; Immune restoration disease

Indexed keywords

ACICLOVIR; ANTIINFLAMMATORY AGENT; ANTIMYCOBACTERIAL AGENT; ANTIRETROVIRUS AGENT; CORTICOSTEROID; FLUCONAZOLE; MYCOBACTERIUM ANTIGEN; NEVIRAPINE; PENTOXIFYLLINE; PROTEINASE INHIBITOR; RITONAVIR; ZIDOVUDINE;

ANTIINFLAMMATORY ACTIVITY; ANTIMICROBIAL THERAPY; ASCITES; CELLULAR IMMUNITY; CEREBROSPINAL FLUID ANALYSIS; CLINICAL FEATURE; CRYPTOCOCCOSIS; CRYPTOCOCCUS; CYTOMEGALOVIRUS INFECTION; DELAYED HYPERSENSITIVITY; DEVELOPING COUNTRY; DISEASE EXACERBATION; ENCEPHALITIS; EPSTEIN BARR VIRUS; FEVER; FOLLICULITIS; GENETIC POLYMORPHISM; GRANULOMATOSIS; GRANULOMATOUS INFLAMMATION; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HEPATOSPLENOMEGALY; HERPES SIMPLEX; HERPES SIMPLEX KERATITIS; HERPES VIRUS; HERPES ZOSTER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNE RESPONSE; IMMUNOPATHOLOGY; IMMUNOPHARMACOLOGY; INFECTION RISK; JC VIRUS; KAPOSI SARCOMA; KERATOCONJUNCTIVITIS; LEUKOPLAKIA; LIVER TOXICITY; LUNG INFILTRATE; LYMPHADENITIS; LYMPHADENOPATHY; MENINGITIS; MYCOBACTERIOSIS; MYCOBACTERIUM; MYCOBACTERIUM INTRACELLULARE AVIUM; NONHODGKIN LYMPHOMA; PAIN; PLEURA EFFUSION; PNEUMOCYSTOSIS; PNEUMONIA; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PYOMYOSITIS; REITER SYNDROME; RETINITIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; SARCOIDOSIS; SKIN LEISHMANIASIS; SPLEEN DISEASE; SUPERINFECTION; T LYMPHOCYTE ACTIVATION; THRUSH; TISSUE NECROSIS; UVEITIS; VIRUS INFECTION;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; AUTOIMMUNE DISEASES; BACTERIAL INFECTIONS; CRYPTOCOCCOSIS; CYTOMEGALOVIRUS INFECTIONS; DEVELOPING COUNTRIES; HEPATITIS; HERPES ZOSTER; HIV INFECTIONS; HIV-1; HUMANS; JC VIRUS; LUNG DISEASES; MYCOBACTERIUM INFECTIONS; RISK FACTORS; VIRUS DISEASES;

EID: 4143090383     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000131375.21070.06     Document Type: Review

References (156)

1. Jacobson M, French M. Altered natural history of AIDS-related opportunistic infections in the era of potent combination antiretroviral therapy. AIDS - A year in Review 1998; 12:S157-S163.
2. Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, d'Arminio Monforte A, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003; 362:22-29.
3. Deayton J, Mocroft A, Wilson P, Emery VC, Johnson MA, Griffiths PD. Loss of cytomegalovirus (CMV) viraemia following highly active antiretroviral therapy in the absence of specific anti-CMV therapy. AIDS 1999; 13:1203-1206.
4. Weinberg A, Wohl DA, MaWhinney S, Barrett RJ, Brown DG, Glomb N, et al. Cytomegalovirus-specific IFN-gamma production is associated with protection against cytomegalovirus reactivation in HIV-infected patients on highly active antiretroviral therapy. AIDS 2003; 17:2445-2450.
5. French MAH, Mallal SA, Dawkins RL. Zidovudine induced restoration of cell-mediated immunity to mycobacteria in immunodeficient HIV-infected patients. AIDS 1992; 6:1293-1297.
6. French MA, Lenzo N, John M, Mallal SA, McKinnon EJ, James IR, et al. Immune restoration disease after the treatment of immunodeficient HIV-infected patients with highly active antiretroviral therapy. HIV Med 2000; 1:107-115.
7. Behrens GM, Meyer D, Stoff M, Schmidt RE. Immune reconstitution syndromes in human immuno-deficiency virus infection following effective antiretroviral therapy. Immunobiology 2000; 202:186-193.
8. Rodriguez-Rosado R, Soriano V, Dona C, Gonzalez-Lahoz J. Opportunistic infections shortly after beginning highly active antiretroviral therapy. Antivir Ther 1998; 3:229-231.
9. Michelet C, Arvieux C, Francois C, Besnier JM, Rogez JP, Breux JP, et al. Opportunistic infections occurring during highly active antiretroviral treatment. AIDS 1998; 12:1815-1822.
10. French MAH. Immune restoration disease in HIV-infected patients on HAART. The AIDS Reader 1999; 9:548-562.
11. DeSimone JA, Pomerantz RJ, Babinchak TJ. Inflammatory reactions in HIV-1 infected persons after initiation of highly active antiretroviral therapy. Ann Intern Med 2000; 133:447-454.
12. Cheng VC, Yuen KY, Chan WM, Wong SS, Ma ES, Chan RM. Immunorestitution disease involving the innate and adaptive response. Clin Infect Dis 2000; 30:882-892.
13. Shelburne SA, III, Hamiff RJ, Rodriguez-Barradas MC, Greenberg SB, Atmar RL, Musher DW, et al. Immune reconstitution inflammatory syndrome; emergence of a unique syndrome during highly active antiretroviral therapy. Medicine (Baltimore) 2002; 81:213-227.
14. Stoll M, Schmidt RE. Immune restoration inflammatory syndromes: the dark side of successful antiretroviral treatment. Curr Infect Dis Rep 2003; 5:266-276.
15. Shelburne SA III, Hamill RJ. The immune reconstitution inflammatory syndrome. AIDS Rev 2003; 5:67-79.
16. Mallal SA, James IR, French MAH. Detection of subclinical Mycobacterium avium intracellulare complex infection in immunodeficient HIV-infected patients treated with zidovudine. AIDS 1994; 8:1263-1269.
17. Race EM, Adelson-Mitty J, Kriegel GR, Barlam TF, Reimann KA, Letvin NL, et al. Focal mycobacterial lymphadenitis following initiation of protease-inhibitor therapy in patients with advanced HIV-1 disease. Lancet 1998; 351:252-255.
18. Dworkin MS, Fratkin MD. Mycobacterium avium complex lymph node abscess after use of highly active antiretroviral therapy in a patient with AIDS. Arch Intern Med 1998; 158:1828-1828.
19. Cabie A, Abel S, Brebion A, Desbois N, Sobesky G. Mycobacterial lymphadenitis after initiation of highly active antiretroviral therapy. Eur J Clin Microbiol Infect Dis 1998; 17:812-813.
20. Phillips P, Kwiatkowski MB, Copland M, Craib K, Montaner J. Mycobacterial lymphadenitis associated with the initiation of combination antiretroviral therapy. J Acquir Immune Defic Syndr Hum Retrovirol 1999; 20:122-128.
21. del Giudice P, Durant J, Counillon E, Mondain V, Bernard E, Roger PM, et al. Mycobacterial cutaneous manifestations: a new sign of immune restoration syndrome in patients with acquired immunodeficiency syndrome. Arch Dermatol 1999; 135:1129-1130.
22. Schwietert M, Battegay M. Focal mycobacterial lymphadenitis after starting highly active antiretroviral treatment. Dtsch med Wschr 1999; 124:45-48.
23. Bartley PB, Allworth AM, Eisen DP. Mycobacterium avium complex causing endobronchial disease in AIDS patients after partial immune restoration. Int J Tuberculosis Lung Dis 1999; 3:1132-1136.
24. Price LM, O'Mahoney C. Focal adenitis developing after immune reconstitution with HAART. Int J STD AIDS 2000; 11:685-686.
25. Hassell M, French MA. Mycobacterium avium infection and immune restoration disease after highly active antiretroviral therapy in a patient with HIV and normal CD4+ counts. Eur J Clin Microbiol Infect Dis 2001; 20:889-891.
26. Salama C, Policar M, Venkataraman M. Isolated pulmonary Mycobacterium avium complex infection in patients with human immunodeficiency virus infection: case reports and literature review. Clin Infect Dis 2003; 37:e35-e40.
27. Lawn SD, Bicanic TA, Macallan DC. Pyomyositis and cutaneous abscesses due to Mycobacterium avium: an immune reconstitution manifestation in a patient with AIDS. Clin Infect Dis 2004; 38:461-463.
28. John M, French MAH. Exacerbation of the inflammatory response to Mycobacterium tuberculosis after antiretroviral therapy. Med J Aust 1998; 169:473-474.
29. Narita M, Ashkin D, Hollender ES, Pitchenik AE. Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS. Am J Respir Crit Care Med 1998; 158:157-161.
30. Crump JA, Tyrer MJ, Lloyd-Owen SJ. Miliary tuberculosis with paradoxical expansion of intracranial tuberculomas complicating human immunodeficiency virus infection in a patient receiving highly active antiretroviral therapy. Clin Infect Dis 1998; 26:1008-1009.
31. Furrer H-I, Malinverni R. Systemic inflammatory reaction after starting highly active antiretroviral therapy in AIDS patients treated for extrapulmonary tuberculosis. Am J Med 1999; 106:371-372.
32. Kunimoto DY, Chui L, Nobert E, Houston S. Immune mediated 'HAART' attack during treatment for tuberculosis. Highly active antiretroviral therapy. Int J Tuberc Lung Dis 1999; 3:944-947.
33. Chien IW, Johnson IL. Paradoxical reactions in HIV and pulmonary TB. Chest 1998; 114:933-936.
34. Fishman JE, Saraf-Lavi E, Narita M, Hollender ES, Ramsinghani R, Ashkin D. Pulmonary tuberculosis in AIDS patients: transient chest radiographic worsening after initiation of antiretroviral therapy. Am J Roentgenol 2000; 174:43-49.
35. Navas E, Martin-Davila P, Moreno L, Pintado V, Casado JL, Fortun J, et al. Paradoxical reactions of tuberculosis in patients with the acquired immunodeficiency syndrome who are treated with highly active antiretroviral therapy. Arch Intern Med 2002; 162:97-99.
36. Lawn SD, Macallan DC. Hypercalcemia: a manifestation of immune reconstitution complicating tuberculosis in an HIV-infected person. Clin Infect Dis 2004; 38:154-155.
37. Sharp MJ, Mallon DFJ. Regional Bacillus Calmette-Guerin lymphadenitis after initiating anti-retroviral therapy in an infant with human immunodeficiency virus type 1 infection. Ped Infect Dis J 1998; 17:660-662.
38. Lawn SD, Wood C, Lockwood DN. Borderline tuberculoid leprosy: an immune reconstitution phenomenon in a human immunodeficiency virus-infected person. Clin Infect Dis 2003; 36:e5-e6.
39. Dannenherg Jr AM. Delayed-type hypersensitivity and cell-mediated immunity in the pathogenesis of tuberculosis. Immunol Today 1991; 12:228-233.
40. Foudraine NA, Hovenkamp E, Notermans DW, Meenhorst PL, Klein MR, Lange JM, et al. Immunopathology as a result of highly active anti-retroviral therapy in HIV-1 infecled patients. AIDS 1999; 13:177-184.
41. French MAH, Cameron PU, Grimsley G, Smyth LA, Dawkins RL. Correction of human immunodeficiency virus-associated depression of delayed-type hypersensitivity (DTH) after zidovudine therapy: DTH, CD4+ T-cell numbers, and epidermal Langerhans cell density are independent variables. Clin Immunol Immunopathol 1990; 55:86-96.
42. Woods ML, MacGinley R, Eisen D, Allworth AM HIV combination therapy: partial immune reconstitution unmasking latent cryptococcal infection. AIDS 1998; 12:1491-1494.
43. Jenny-Avital ER, Abadi M. Immune reconstitution cryptococcosis after initiation of successful highly active antiretroviral therapy. Clin Infect Dis 2002; 35:e128-e133.
44. Blanche P, Gombert B, Ginsburg C, Passeron A, Stubei I, Rigolet A, et al. HIV combination therapy: immune restitution causing cryptococcal lymphadenitis dramatically improved by anti-inflammatory therapy. Scand J Infect Dis 1998; 30:615-616.
45. Lanzafame M, Trevonzoli M, Carretta C, Lazzarini L, Vento S, Concia F. Mediastinal lymphadenitis due to cryptococcal infection in HIV-positive patients on highly active antiretroviral therapy. Chest 1999; 116:848-849.
46. Trevenzoli M, Cattelan AM, Rea F, Sasset L, Semisa M, Lanzafame M, et al. Mediastinitis due to cryptococcal infection: a new clinical entity in the HAART era. J Infect 2002; 45:173-179.
47. Cinti SK, Armstrong WS, Kauffman CA. Case report. Recurrence of increased intracranial pressure with antiretroviral therapy in an AIDS patient with cryptococcal meningitis. Mycoses 2001; 44:497-501.
48. Rambeloarisoa J, Batisse D, Thiebaut JB, Mikol J, Mrejen S, Karmochkine M, et al. Intramedullary abscess resulting from disseminated cryptococcosis despite immune restoration in a patient with AIDS. J Infect 2002; 44: 185-188.
49. Breton G, Seilhean D, Cherin P, Herson S, Benveniste O. Paradoxical intracranial cryptococcoma in a human immunodeficiency virus-infected man being treated with combination antiretroviral therapy. Am J Med 2002; 113:155-157.
50. Wislez M, Bergot E, Antoine M, Parrot A, Carette MF, Mayaud C, et al. Acute respiratory failure following HAART introduction in patients treated for Pneumocystis carinii pneumonia. Am J Respir Crit Care Med 2001; 164:847-851.
51. Dean GL, Williams DI, Churchill DR, Fisher MJ. Transient clinical deterioration in HIV patients with Pneumocyslis carinii pneumonia after starting highly active antiretroviral therapy: another case of immune restoration inflammatory syndrome. Am J Respir Crit Care Med 2002; 165:1670.
52. Koval CE, Gigliotti F, Nevins D, Demeter LM. Immune reconstitution syndrome after successful treatment of Pneumocystis carinii pneumonia in a man with human immunodeficiency virus type 1 infection. Clin Infect Dis 2002; 35:491-493.
53. Wit FW, Weverling GJ, Weel I, Jurriaans S, Lange JM. Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. J Infect Dis 2002; 186: 23-31.
54. Puoti M, Torti C, Ripamonti D, Castelli F, Zaltron S, Zanini B, et al. Severe hepatotoxicity during combination antiretroviral treatment: incidence, liver histology, and outcome. J Acquir Immune Defic Syndr 2003; 32:259-267.
55. Law WP, Dore GJ, Duncombe CI, Mahanontharit A, Boyd MA, Ruxrungtham K, et al. Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996-2001. AIDS 2003; 17:2191-2199.
56. Carr A, Cooper DA. Restoration of immunity to chronic hepatitis B infection in HIV-infected patients on protease inhibitors. Lancet 1997; 349:995-996.
57. John M, Flexman J, French M. Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: an 'immune restoration disease'? AIDS 1998; 12:2289-2293.
58. Martin-Carbonero L, Nunez M, Rios P, Perez-Olmeda M, Gonzalez-Lahoz J, Soriano V. Liver injury after beginning antiretroviral therapy in HIV/hepatitis C virus co-infected patients is not related to immune reconstitution. AIDS 2002; 16:1423-1425.
59. Valiante NM, D'Andrea A, Crotta S, Lechner F, Klenerman P, Nuti S, et al. Life, activation and death of intrahepatic lymphocytes in chronic hepatitis C. Immunol Rev 2000; 174:77-89.
60. Michelet C, Chapplain JM, Petsaris O, Arvieux C, Ruffault A, Lotteau V, et al. Differential effect of ritonavir and indinavir on immune response to hepatitis C virus in HIV-1 infected patients. AIDS 1999; 13:1995-1996.
61. Stone SF, Lee S, Keane NM, Price P, French MA. Association of increased hepatitis C virus (HCV)-specific IgG and soluble CD26 dipeptidyl peptidase IV enzyme activity with hepatotoxicity after highly active antiretroviral therapy in human immunodeficiency virus-HCV-coinfected patients. J Infect Dis 2002; 186:1498-1502.
62. Proost P, Schutyser E, Menten P, Struyf S, Wuyts A, Opdenakker G, et al. Amino-terminal truncation of CXCR3 agonists impairs receptor signaling and lymphocyte chemotaxis, while preserving antiangiogenic properties. Blood 2001; 98:3554-3561.
63. Harvey CE, Post JJ, Palladinetti P, Freeman AJ, Ffrench RA, Kumar RK, et al. Expression of the chemokine IP-10 (CXCL10) by hepatocytes in chronic hepatitis C virus infection correlates with histological severity and lobular inflammation. J Leukoc Biol 2003; 74:360-369.
64. Zylberberg H, Pialoux G, Carnot F, Landau A, Brechot C, Pol S. Rapidly evolving hepatitis C virus - related cirrhosis in a human immunodeficiency virus-infected patient receiving triple antiretroviral therapy. Clin Infect Dis 1998; 27:1255-1258.
65. Murcia JM, Boix V, Merino E, Manso MI, Portilla J. Drug toxicity or syndrome of immune restoration causing fulminant cirrhosis after HAART-induced immune recovery. Eur J Clin Microbiol Infect Dis 2002; 21:153-155.
66. Qurishi N, Kreuzberg C, Luchters G, Effenberger W, Kupfer B, Sauerbruch T, et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet 2003; 362:1708-1713.
67. Martin-Carbonero L, Benhamou Y, Puoti M, Berenguer J, Mallolas J, Quereda C, et al. Incidence and predictors of severe liver fibrosis in human immunodeficiency virus-infected patients with chronic hepatitis C: a European collaborative study. Clin Infect Dis 2004; 38:128-133.
68. Uberti-Foppa C, De Bona A, Morsica G, Galli L, Gallotta G, Boeri E, et al. Pretreatment of chronic active hepatitis C in patients coinfected with HIV and hepatitis C virus reduces the hepatotoxicity associated with subsequent antiretroviral therapy. J Acquir Immune Defic Syndr 2003; 33:146-152.
69. Mastroianni CM, Trinchieri V, Santopadre P, Lichtner M, Forcina G, D'Agostino C, et al. Acute clinical hepatitis in an HIV-seropositive hepatitis B carrier receiving protease inhibitor therapy. AIDS 1998; 12:1939-1940.
70. Velasco M, Moran A, Tellez MJ. Resolution of chronic hepatitis B after ritonavir treatment in an HIV-infected patient. N Engl J Med 1999; 340:1765-1766.
71. Proia LA, Ngui SL, Kaur S, Kessler HA, Trenbolme GM. Reactivation of hepatitis B in patients with human immunodeficiency virus infection treated with combination antiretroviral therapy. Am J Med 2000; 108:249-251.
72. Manegold C, Hannoun C, Wywiol A, Dietrich M, Polywka S, Chiwakata CB, et al. Reactivation of hepatitis B virus replication accompanied by acute hepatitis in patients receiving highly active antiretroviral therapy. Clin Infect Dis 2001; 32:144-148.
73. Rouanet I, Peyriere H, Mauboussin JM, Terrail N, Vincent D. Acute clinical hepatitis by immune restoration in a human immunodeficiency virus/hepatitis B virus co-infected patient receiving antiretroviral therapy. Eur J Gastroenterol Hepatol 2003; 15:95-97.
74. Jacobson MA, Zegans M, Pavan PR, O'Donnell JJ, Sattler F, Rao N, et al. Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy. Lancet 1997; 349:1443-1445.
75. Casado JL, Arrizabalaga I, Montes M, Marti-Belda P, Tural C, Pinilla J, et al. Incidence and risk factors for developing cylomegalovirus retinitis in HIV-infected patients receiving protease inhibitor therapy. Spanish CMV-AIDS Study Group. AIDS 1999; 13:1497-1502.
76. Casado JL, Perez-Elias MJ, Marti-Belda P, Antela A, Suarez M, Ciancas E, et al. Improved outcome of cytomegalovirus retinitis in AIDS patients after introduction of protease inhibitors. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 19:130-134.
77. Tay-Kearney ML, French MAH, Mallal S. CMV retinitis in transition. Aust NZ J Ophthalmol 1999; 27:89-89.
78. Karavellas MP, Lowder CY, Macdonald C, Avila CP, Jr., Freeman WR. Immune recovery vitritis associated with inactive cytomegalovirus retinitis: a new syndrome. Arch Ophthalmol 1998; 116:169-175.
79. Zegans ME, Walton RC, Holland GN, O'Donnell JI, Jacobson MA, Margolis TP. Transient vitreous inflammatory reactions associated with combination antiretroviral therapy in patients with AIDS and cytomegalovirus retinitis. Am J Ophthalmol 1998; 125:292-300.
80. Nguyen QD, Kempen JH, Bolton SC, Dunn JP, Jabs DA. Immune recovery uveitis in patients with AIDS and cytomegalovirus retinitis after highly active antiretroviral therapy. Am J Ophthalmol 2000; 129:634-639.
81. Karavellas MP, Azen SP, Macdonald JC, Shufelt CL, Lowder CY, Plummer DJ, et al. Immune recovery vitritis and uveitis in AIDS: clinical predictors, sequelae, and treatment outcomes. Retina 2001; 21:1-9.
82. Robinson MR, Csaky KG, Lee SS, Masur H, Polis MA. Fibrovascular changes misdiagnosed as cytomegalovirus retinitis reactivation in a patient wilh immune recovery. Clin Infect Dis 2004; 38:139-141.
83. Hsieh S-M, Pan S-C, Hung C-C, Tsai H-C, Chen M-Y, Chang S-C. Association between cytomegalovirus-specific reactivity of T cell subsets and development of cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome. J Infect Dis 2001; 184:1386-1391.
84. Gerna C, Piceinini G, Genini E, Percivalle E, Zavattoni M, Lilleri D, et al. Declining levels of rescued lymphoproliferative response to human cytomegalovirus (HCMV) in AIDS patients with or without HCMV disease following long-term HAART. J Acquir Immune Defic Syndr 2001; 28:320-331.
85. Keane NM, Price P, Lee S, Almeida C-A, Stone SF, James I, et al. Restoration of CD4 T-cell responses to cytomegalovirus is short-lived in severely immunodeficient HIV patients responding to highly active antiretroviral therapy. HIV Med (in press).
86. Stone SF, Price P, Tay-Kearney M-L, French MA. Cytomegalovirus (CMV) retinitis immune restoration disease occurs during highly active antiretroviral therapy-induced restoration of CMV-specific immune responses within a predominant Th2 cytokine environment. J Infect Dis 2002; 185:1813-1817.
87. Stone SF, Price P, Brochier J, French MA. Plasma bioavailable interleukin-6 is elevated in human immunodeficiency virus-infected patients who experience herpesvirus-associated immune restoration disease after start of highly active antiretroviral therapy. J Infect Dis 2001; 184:1073-1077.
88. Podack ER, Strbo N, Sotosec V, Muta H. CD30-governor of memory T cells? Ann NY Acad Sci 2002; 975:101-113.
89. Mutimer HP, Akatsuka Y, Manley T, Cbuang EL, Boeckb M, Harrington R, et al. Association between immune recovery uveitis and a diverse intraocular cytomegalovirus-specific cytotoxic T cell response. J Infect Dis 2002; 186:701-705.
90. Aldeen T, Hay P, Davidson F, Lau R. Herpes zoster infection in HIV-seropositive patients associated with highly active antiretroviral therapy. AIDS 1998; 12:1719-1720.
91. Martinez E, Gatell J, Moran Y, Aznar E, Buira E, Guelar A, et al. High incidence of herpes zoster in patients with AIDS soon after therapy with protease inhibitors. Clin Infect Dis 1998; 27:1510-1513.
92. Domingo P, Torres OH, Ris J, Vazquez G. Herpes zoster as an immune reconstitution disease after initiation of combination antiretroviral therapy in patients with human immunodeficiency virus type-1 infection. Am J Med 2001; 110:605-609.
93. Clark BM, Krueger RG, Price P, French MAH. Compartmentalisation of the immune response in varicella zoster virus immune restoration disease causing transverse myelitis. AIDS 2004; 18:1218-1221.
94. Naseri A, Margolis TP. Varicella zoster virus immune recovery stromal keratitis in a patient with AIDS. Br J Ophthalmol 2001; 85:1390-1391.
95. Fox PA, Barton SE, Francis N, Youle M, Henderson DC, Pillay D, et al. Chronic erosive herpes simplex virus infection of the penis, a possible immune reconstitution disease. HIV Med 1999; 1:10-18.
96. Cinque P, Pierotti C, Vigano MG, Bestetti A, Fausti C, Bertelli D, et al. The good and evil of HAART in HIV-related progressive multifocal leukoencephalopathy. J Neurovirol 2001; 7:358-363.
97. Gasnault I, Kahraman M, de Goer de Herve MG, Durali D, Delfraissy JF, Taoufik Y. Critical role of JC virus-specific CD4 T-cell responses in preventing progressive multifocal leukoencephalopathy. AIDS 2003; 17:1443-1449.
98. Mayo H, Collazos J, Martinez E. Progressive multifocal leukoencephalopathy following initiation of highly active anti-retroviral therapy. AIDS 1998; 12:1720-1722.
99. Kotecha N, George MJ, Smith TW, Corvi F, Litofsky NS. Enhancing progressive multifocal leukoencephalopathy: an indicator of improved immune status? Am J Med 1998; 105:541-543.
100. Tantisiriwat W, Tebas P, Clifford DB, Powderly WC, Fichtenbaum CJ. Progressive multifocal leukoencephalopathy in patients with AIDS receiving highly active antiretroviral therapy. Clin Infect Dis 1999; 28:1152-1154.
101. Miralles P, Berenguer J, Lacruz C, Cosin J, Lopez JC, Padilla B, et al. Inflammatory reactions in progressive multifocal leukoencephalopathy after highly active antiretroviral therapy. AIDS 2001; 15:1900-1902.
102. Safdar A, Rubocki RJ, Horvath IA, Narayan KK, Waldron RL. Fatal immune restoration disease in human immunodeficiency virus type 1-infected patients with progressive multifocal leukoencephalopathy: impact of antiretroviral therapy-associated immune reconstitution. Clin Infect Dis 2002; 35:1250-1257.
103. Hoffmann C, Horst HA, Albrecht H, Schlote W. Progressive multifocal leucoencephalopathy with unusual inflammatory response during antiretroviral treatment. J Neurol Neurosurg Psychiatry 2003; 74:1142-1144.
104. Nolan RC, Chidlow G, French MA. Parvovirus B19 encephalitis presenting as immune restoration disease after highly active antiretroviral therapy for human immunodeficiency virus infection. Clin Infect Dis 2003; 36:1191-1194.
105. Bouscarat F, Maubec E, Matheron S, Descamps V. Immune recovery inflammatory folliculitis. AIDS 2000; 14:617-618.
106. Blanche P, Gombert B, Rivoal O, Abad S, Salmon D, Brezin A. Uveitis due to Leishmania major as part of HAART-induced immune restitution syndrome in a patient with AIDS. Clin Infect Dis 2002; 34:1279-1280.
107. Ridolfo AL, Cervasoni C, Antinori S, Pizzuto M, Santambrogio S, Trabattoni D, et al. Post-kala-azar dermal leishmaniasis during highly active antiretroviral therapy in an AIDS patient infected with Leishmania infantum. J Infect 2000; 40:199-202.
108. Abino IF, Peraldi R, Lepidi H, Luciani M, Girard PM. Bacillary splenitis (Bartonella henselae) during immune restoration in an HIV-infected patient. AIDS 2002; 16:1429-1430.
109. Gajdatsy AD, Tay-Kearney ML. Microsporidial keratoconjunctivitis after HAART. Clin Exp Ophthalmol 2001; 29:327-329.
110. Neumann S, Kreth F, Schubert S, Mossner I, Caca K. Reiter's syndrome as a manifestation of an immune reconstitution syndrome in an HIV-infected patient: successful treatment with doxycycline. Clin Infect Dis 2003; 36:1628-1629.
111. Greenspan D, Canchola AJ, MacPhail LA, Cheikh B, Greenspan JS. Effect of highly active antiretroviral therapy on frequency of oral warts. Lancet 2001; 357:1411-1412.
112. King MD, Reznik DA, O'Daniels CM, Larsen NM, Osterholt D, Blumberg HM. Human papillomavirus-associated oral warts among human immunodeficiency virus-seropositive patients in the era of highly active antiretroviral therapy: an emerging infection. Clin Infect Dis 2002; 34:641-648.
113. Collazos J, Ojanguren J, Mayo J, Martinez E, Ibarra S. Lymphoma developing shortly after the onset of highly active antiretroviral therapy in HIV-infected patients. AIDS 2002; 16:1304-1306.
114. Marshall NA, Vickers MA, Barker RN. Regulatory T cells secreting IL-10 dominate the immune response to EBV latent membrane protein 1. J Immunol 2003; 170:6183-6189.
115. Breen EC, Boscardin WJ, Detels R, Jacobson LP, Smith MW, O'Brien SJ, et al. Non-Hodgkin's B cell lymphoma in persons with acquired immunodeficiency syndrome is associated with increased serum levels of IL10, or the IL10 promoter -592 C/C genotype. Clin Immunol 2003; 109:119-129.
116. Weir A, Wansbrough-Jones M. Mucosal Kaposi's sarcoma following protease inhibitor therapy in an HIV-infected patient. AIDS 1997; 11:1895-1896.
117. Zietz C, Bogner JR, Goebel FD, Lohrs U. An unusual cluster of cases of Castleman's disease during highly active antiretroviral therapy for AIDS. N Engl Med 1999; 340:1923-1924.
118. Phillips P, Chan K, Hogg R, Bessuille E, Black W, Talbot J, et al. Azithromycin prophylaxis for Mycobacterium avium complex during the era of highly active antiretroviral therapy: evaluation of a provincial program. Clin Infect Dis 2002; 34:371-378.
119. Price P, Keane NM, Stone SF, Cheong KYM, French MA. MHC haplotypes affect the expression of opportunistic infections in HIV patients. Hum Immunol 2001; 62:157-164.
120. Price P, Morahan G, Huang D, Stone E, Cheong KY, Castley A, et al. Polymorphisms in cytokine genes define subpopulations of HIV-1 patients who experienced immune restoration diseases. AIDS 2002; 16:2043-2047.
121. Naccache JM, Antoine M, Wislez M, Fleury-Feith J, Oksenhendler E, Mayaud C, et al. Sarcoid-like pulmonary disorder in human immunodeficiency virus-infected patients receiving antiretroviral therapy. Am J Respir Crit Care Med 1999; 159:2009-2013.
122. Mirmirani P, Maurer TA, Herndier B, McGrath M, Weinstein MD, Berger TC. Sarcoidosis in a patient with AIDS: a manifestation of immune restoration syndrome. J Am Acad Dermatol 1999; 41:285-286.
123. Gomez V, Smith PR, Burack J, Daley R, Rosa U. Sarcoidosis after antiretroviral therapy in a patient with acquired immunodeficiency syndrome. Clin Infect Dis 2000; 31:1278-1280.
124. Blanche P, Gombert B, Rollot F, Salmon D, Sicard D. Sarcoidosis in a patient with acquired immunodeficiency syndrome treated with interleukin-2. Clin Infect Dis 2000; 31:1493-1494.
125. Haramati LB, Lee G, Singh A, Molina PL, White CS. Newly diagnosed pulmonary sarcoidosis in HIV-infected patients. Radiology 2001; 218:242-246.
126. Zandman-Goddard G, Peeva E, Barland P. Combined autoimmune disease in a patient with AIDS. Clin Rheumatol 2002; 21:70-72.
127. Foulon G, Wislez M, Naccache JM, Blanc FX, Rabbat A, Israel-Biet D, et al. Sarcoidosis in HIV-infected patients in the era of highly active antiretroviral therapy. Clin Infect Dis 2004; 38:418-425.
128. Blanche P, Passeron A, Gombert B, Ginsburg C, Salmon D, Sicard D. Sarcoidosis and HIV infection: influence of highly active antiretroviral therapy. Br J Dermatol 1999; 140:1185
129. Trevenzoli M, Cattelan AM, Marino F, Marchioro U, Cadrobbi P. Sarcoidosis and HIV infection: a case report and a review of the literature. Postgrad Med J 2003; 79:535-538.
130. Viani RM. Sarcoidosis and interstitial nephritis in a child with acquired immunodeficiency syndrome: implications of immune reconstitution syndrome with an indinavir-based regimen. Pediatr Infect Dis J 2002; 21:435-438.
131. Behrens G, Knuth C, Schedel I, Mendila M, Schmidt RE. Highly active antiretroviral therapy. Lancet 1998; 351:1057-1058.
132. Diri E, Lipsky PE, Berggren RE. Emergence of systemic lupus erythematosus after initiation of highly active antiretroviral therapy for human immunodeficiency virus infection. J Rheumatol 2000; 27:2711-2714.
133. Sellier P, Monsuez II, Evans J, Minozzi C, Passeron J, Vittecoq D, et al. Human immunodeficiency virus-associated polymyositis during immune restoration with combination antiretroviral therapy. Am J Med 2000; 109:510-512.
134. Bell C, Nelson M, Kaye S. A case of immune reconstitution rheumatoid arthritis. Int J STD AIDS 2002; 13:580-581.
135. Makela P, Howe L, Glover S, Ferguson I, Pinto A, Gompels M. Recurrent Guillain-Barre syndrome as a complication of immune reconstitution in HIV. J Infect 2002; 44:47-49.
136. Piliero PJ, Fish DG, Preston S, Cunningham D, Kinchelow T, Salgo M, et al. Guillain-Barre syndrome associated with immune reconstitution. Clin Infect Dis 2003; 36:e111-e114.
137. Jubault V, Penfornis A, Schillo F, Hoen B, Izembart M, Timsit J, et al. Sequential occurrence of thyroid autoantibodies and Graves' disease after immune restoration in severely immunocompromised human immunodeficiency virus-1-infected patients. J Clin Endocrinol Metab 2000; 85:4254-4257.
138. Sereti I, Sarlis NJ, Arioglu E, Turner ML, Mican JM. Alopecia universalis and Graves' disease in the setting of immune restoration after highly active antiretroviral therapy. AIDS 2001; 15:138-140.
139. French MA, Lewin SR, Dykstra C, Krueger R, Price P, Leedman PJ. Graves' disease during immune reconstitution after highly active antiretroviral therapy for HIV infection: evidence of thymic dysfunction. AIDS Res Hum Retroviruses 2004; 20:157-162.
140. Silvestre JF, Albares MP, Ramon R, Botella R. Cutaneous intolerance to tattoos in a patient with human immunodeficiency virus: a manifestation of the immune restoration syndrome. Arch Dermatol 2001; 137:669-670.
141. Wimalasundera RC, Larbalestier N, Smith JH, de Ruiter A, McG Thom SA, Hughes AD, et al. Pre-eclampsia, antiretroviral therapy, and immune reconstitution. Lancet 2002; 360:1152-1154.
142. van der Ven AJ, van Oostenbrugge RJ, Kubat B, Tervaert JW. Cerebral vasculitis after initiation of antiretroviral therapy. AIDS 2002; 16:2362-2364.
143. Rogers CD, French MAH. Peyronie's disease in men with HIV responding to highly active antiretroviral therapy. HIV Med 2004; 5:185-186.
144. Bachmeyer C, Cordier F, Blum L, Cazier A, Verola O, Aractingi S. Multiple eruptive dermatofibromas after highly active antiretroviral therapy. Br J Dermatol 2000; 143:1336-1337.
145. Casariego Z, Pombo T, Perez H, Patterson P. Eruptive cheilitis: a new adverse effect in reactive HIV-positive patients subjected to high activity antiretroviral therapy (HAART). Presentation of six clinical cases. Med Oral 2001; 6:19-30.
146. Tassie JM, Szumilin E, Calmy A, Goemaere E. Highly active antiretroviral therapy in resource-poor settings: the experience of Medecins Sans Frontieres. AIDS 2003; 17:1995-1997.
147. Sungkanuparph S, Vibhagool A, Mootsikapun P, Chetchotisakd P, Tansuphaswaswadikul S, Bowonwatanuwong C. Opportunistic infections after the initiation of highly active antiretroviral therapy in advanced AIDS patients in an area with a high prevalence of tuberculosis. AIDS 2003; 17:2129-2131.
148. Klein D, Hurley LB, Merrill D, Quesenberry CP, Jr. Review of medical encounters in the 5 years before a diagnosis of HIV-1 infection: implications for early detection. J Acquir Immune Defic Syndr 2003; 32:143-152.
149. Murray R, Mallal S, Heath C, French M. Cerebral Mycobacterium avium infection in an HIV-infected patient following immune reconstitution and cessation of therapy for disseminated Mycobacterium avium complex infection. Eur J Clin Microbiol Infect Dis 2001; 20:199-201.
150. Aberg JA, Chin-Hong PV, McCutchan A, Koletar SL, Currier JS. Localized osteomyelitis due to Mycobacterium avium complex in patients with Human Immunodeficiency Virus receiving highly active antiretroviral therapy. Clin Infect Dis 2002; 35:E8-E13.
151. Lee S, French MAH, Price P. Interleukin-23 and interferon-gamma deficiency in immunodeficient HIV patients who achieved a long-term increase in CD4 T-cell counts on HAART. AIDS 2004; 18:1337-1340.
152. Stone SF, Price P, Keane NM, Murray RJ, French MA. Levels of IL-6 and soluble IL-6 receptor are increased in HIV patients with a history of immune restoration disease after HAART. HIV Med 2002; 3.21-27.
153. Morlese JF, Orkin CM, Abbas R, Burton C, Qazi NA, Nelson MR, et al. Plasma IL-6 as a marker of mycobacterial immune restoration disease in HIV-1 infection. AIDS 2003; 17:1411-1413.
154. Almeida CA, Price P, French MA. Immune activation in patients infected with HIV type 1 and maintaining suppression of viral replication by highly active antiretroviral therapy. AIDS Res Hum Retroviruses 2002; 18:1351-1355.
155. Dandona P, Aljada A, Bandyopadhyay A. Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol 2004; 25:4-7.
156. Brown TT, Cole SR, Li X, Kingsley LA, Palella FJ, Riddler SA, et al. Prevalence and incidence of pre-diabetes and diabetes in the Multicentre AIDS Cohort Study. XI Conference on Retroviruses and Opportunistic Infections, San Francisco, February 2004 [abstract no. 73].